Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016

  • ID: 3804680
  • Report
  • 65 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Cleveland BioLabs, Inc.
  • Neuropore Therapies, Inc.
  • Vascular Biogenics Ltd.
  • MORE
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016

Summary

‘Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2)
- The report reviews Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Cleveland BioLabs, Inc.
  • Neuropore Therapies, Inc.
  • Vascular Biogenics Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Overview

Therapeutics Development

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Stage of Development

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Therapy Area

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Indication

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Companies

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Products under Development by Universities/Institutes

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Companies Involved in Therapeutics Development

Cleveland BioLabs, Inc.

Neuropore Therapies, Inc.

Opsona Therapeutics Limited

Vascular Biogenics Ltd.

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Drug Profiles

CBLB-612 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBLB-613 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-220 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-13 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-MAPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TLR2 for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR-1 and TLR-2 for Infectious Disease and Neuroinflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Target PPAR-Gamma and TLR-2 and IBD and Tissue Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Dormant Projects

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Discontinued Products

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Featured News & Press Releases

May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study

Jan 26, 2016: Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation

Jul 13, 2015: Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation

Apr 02, 2015: Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612

Mar 16, 2015: Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation

Mar 02, 2015: Opsona Therapeutics commences Part B of phase II study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor renal transplant recipients at high risk of Early Graft Dysfunction

Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof

Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof

Feb 17, 2015: VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis

Feb 09, 2015: VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease

Feb 06, 2015: VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology

Jan 29, 2015: VBL Therapeutic In Cooperation With KCR Reported LPO In Phase 2 Of VB-201

Jan 27, 2015: Opsona Therapeutics initiates phase I / II prospective open in patients with myelodysplastic syndrome second line of lower level (low and intermediate-1) with OPN-305 label ...

Jan 27, 2015: Opsona Therapeutics OPN-305 examines pretreatment myelodysplasia

Jan 26, 2015: Opsona Therapeutics initiates a prospective open label Phase I/II study in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) with OPN-305, a First-in Class Monoclonal

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 65List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Cleveland BioLabs, Inc., H2 2016

Pipeline by Neuropore Therapies, Inc., H2 2016

Pipeline by Opsona Therapeutics Limited, H2 2016

Pipeline by Vascular Biogenics Ltd., H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Dormant Projects (Contd..2), H2 2016

Discontinued Products, H2 2016 54List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Cleveland BioLabs, Inc.
  • Neuropore Therapies, Inc.
  • Vascular Biogenics Ltd.
  • MORE
According to our recently published report 'Toll Like Receptor 2 – Pipeline Review, H2 2016'; Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says; Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Toll-like receptor 2 also known as TLR2 is a protein encoded by the TLR2 gene. It acts via MYD88 and TRAF6 leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. It promotes apoptosis in response to lipoproteins. It recognizes MALP-2, soluble tuberculosis factor, phenol-soluble modulin and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6. It acts as a receptor for M.tuberculosis lipoproteins LprA, LprG, LpqH and PhoS1 (pstS1), some lipoproteins are dependent on other coreceptors (TLR1, CD14 and/or CD36). The lipoproteins act as agonists to modulate antigen presenting cell functions in response to the pathogen.

The report 'Toll Like Receptor 2 – Pipeline Review, H2 2016' outlays comprehensive information on the Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Cleveland BioLabs, Inc.
Neuropore Therapies, Inc.
Opsona Therapeutics Limited
Vascular Biogenics Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll